Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

Mortality of people living with HIV in Paris Area from 2011 to 2015.

Sellier P, Hamet G, Brun A, Ponscarme D, De Castro N, Alexandre G, Rozenbaum W, Molina JM, Abgrall S.

AIDS Res Hum Retroviruses. 2019 Sep 29. doi: 10.1089/AID.2019.0143. [Epub ahead of print]

PMID:
31565958
2.

Does region of origin influence the timing and outcome of first-line antiretroviral therapy in France?

Gatey C, Brun A, Hamet G, Diamantis S, Sellier P, Bouchaud O, Garrait V, Rozenbaum W, Molina JM, Abgrall S; COREVIH Ile de France Est Research Group.

HIV Med. 2019 Feb;20(2):175-181. doi: 10.1111/hiv.12697. Epub 2018 Dec 3.

PMID:
30506853
3.

Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.

Noret M, Balavoine S, Pintado C, Siguier M, Brun A, Bauer R, Loze B, Leplatois A, Aslan A, Moudachirou K, Delaugerre C, Rozenbaum W, Molina JM.

AIDS. 2018 Sep 24;32(15):2161-2169. doi: 10.1097/QAD.0000000000001939.

PMID:
30212403
4.

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF; ANRS IPERGAY Study Group.

N Engl J Med. 2015 Dec 3;373(23):2237-46. doi: 10.1056/NEJMoa1506273. Epub 2015 Dec 1.

5.

Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study.

Gazaignes S, Resche-Rigon M, Gatey C, Yang C, Denis B, Fonsart J, Desseaux K, Guionie M, Rozenbaum W, Delaugerre C, Molina JM.

Antivir Ther. 2016;21(4):329-36. doi: 10.3851/IMP3010. Epub 2015 Nov 13.

PMID:
26566057
6.

Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study.

Gazaignes S, Resche-Rigon M, Yang C, Gatey C, Munier AL, Desseaux K, Rozenbaum W, Molina JM.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19796. doi: 10.7448/IAS.17.4.19796. eCollection 2014.

7.

Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.

Potard V, Rey D, Poizot-Martin I, Mokhtari S, Pradier C, Rozenbaum W, Brun-Vezinet F, Costagliola D; FHDH ANRS CO4 (French Hospital Database on HIV, Agence Nationale de Recherches sur le Sida, cohort 4).

J Int AIDS Soc. 2014 Sep 25;17:19070. doi: 10.7448/IAS.17.1.19070. eCollection 2014.

8.

Challenges and opportunities for oral pre-exposure prophylaxis in the prevention of HIV infection: where are we in Europe?

Molina JM, Pintado C, Gatey C, Ponscarme D, Charbonneau P, Loze B, Rozenbaum W, Delaugerre C.

BMC Med. 2013 Aug 23;11:186. doi: 10.1186/1741-7015-11-186. Review.

9.

French HIV experts on early antiretroviral treatment for prevention: uncertainty and heterogeneity.

Lebouché B, Engler K, Lévy JJ, Gilmore N, Spire B, Rozenbaum W, Lacene T, Routy JP.

J Int Assoc Provid AIDS Care. 2014 Mar-Apr;13(2):160-9.

PMID:
23761218
10.

Minimal interference: A basis for selecting ART for prevention with positives.

Lebouché B, Engler K, Lévy JJ, Gilmore N, Spire B, Rozenbaum W, Routy JP.

AIDS Care. 2013;25(10):1284-90. doi: 10.1080/09540121.2013.764394. Epub 2013 Feb 11.

PMID:
23394079
11.

What is a modest public health impact?

Yazdanpanah Y, Walensky RP, Rozenbaum W, Yeni P, Paltiel AD.

Arch Intern Med. 2012 Mar 26;172(6):521-2; author reply 522-3. doi: 10.1001/archinternmed.2011.1876. No abstract available.

PMID:
22450944
12.

Antiretroviral therapy initiation in France: adherence to national guidelines and outcome.

Latthaphasavang V, Bouldouyre MA, Rachline A, Ponscarme D, Rozenbaum W, Mary JY, Delaugerre C, Molina JM.

J Int Assoc Physicians AIDS Care (Chic). 2012 Jan-Feb;11(1):40-6. doi: 10.1177/1545109711418362. Epub 2011 Aug 31.

PMID:
21880977
13.

Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial).

Gallien S, Journot V, Rozenbaum W, Yéni P, Morlat P, Poizot-Martin I, Reynes J, Reliquet V, Leclercq P, Simon F, Chêne G, Molina JM; ALIZE (ANRS 099) Study Group.

J Antimicrob Chemother. 2011 Jan;66(1):184-91. doi: 10.1093/jac/dkq395. Epub 2010 Oct 28.

PMID:
21036772
14.

Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting.

Pavie J, Rachline A, Loze B, Niedbalski L, Delaugerre C, Laforgerie E, Plantier JC, Rozenbaum W, Chevret S, Molina JM, Simon F.

PLoS One. 2010 Jul 19;5(7):e11581. doi: 10.1371/journal.pone.0011581.

15.

A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy.

Raboud JM, Diong C, Carr A, Grinspoon S, Mulligan K, Sutinen J, Rozenbaum W, Cavalcanti RB, Wand H, Costagliola D, Walmsley S; Glitazone and Lipoatrophy Meta-Analysis Working Group.

HIV Clin Trials. 2010 Jan-Feb;11(1):39-50. doi: 10.1310/hct1101-39.

16.

Bridging the gap: the patient-doctor relationship.

Rozenbaum W'.

Pneumonol Alergol Pol. 2009;77(3):314-9. Review. No abstract available.

17.

Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.

Valantin MA, Lanoy E, Bentata M, Kalmykova O, Boutekadjirt A, Allavena C, Rozenbaum W, Peytavin G, Amellal B, Calvez V, Costagliola D, Katlama C; NoNuke ANRS 108 Study Team.

HIV Med. 2008 Oct;9(8):625-35. doi: 10.1111/j.1468-1293.2008.00606.x. Epub 2008 Jul 8.

18.

[How to lower HIV infection incidence using public health principles].

Rozenbaum W.

Rev Epidemiol Sante Publique. 2008 Jun;56(3):139-42. doi: 10.1016/j.respe.2008.04.001. Epub 2008 May 16. French. No abstract available.

PMID:
18486381
19.

Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).

Slama L, Lanoy E, Valantin MA, Bastard JP, Chermak A, Boutekatjirt A, William-Faltaos D, Billaud E, Molina JM, Capeau J, Costagliola D, Rozenbaum W.

Antivir Ther. 2008;13(1):67-76.

PMID:
18389900
20.

Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study.

Pialoux G, Quercia RP, Gahery H, Daniel N, Slama L, Girard PM, Bonnard P, Rozenbaum W, Schneider V, Salmon D, Guillet JG.

Clin Vaccine Immunol. 2008 Mar;15(3):562-8. doi: 10.1128/CVI.00165-07. Epub 2008 Jan 9.

21.

First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.

Potard V, Rey D, Mokhtari S, Frixon-Marin V, Pradier C, Rozenbaum W, Brun-Vezinet F, Costagliola D; French Hospital Database on HIV, ANRS C04.

Antivir Ther. 2007;12(3):317-24.

PMID:
17591021
22.

Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study.

De Truchis P, Kirstetter M, Perier A, Meunier C, Zucman D, Force G, Doll J, Katlama C, Rozenbaum W, Masson H, Gardette J, Melchior JC.

J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):278-85.

PMID:
17179770
23.

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.

Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, Rozenbaum W, Le Teuff G, Trylesinski A, Piketty C; TECOVIR Study Group.

Hepatology. 2006 Mar;43(3):548-55.

PMID:
16496322
24.

Outbreak of syphilis among HIV-infected patients: descriptive data from a Parisian hospital.

Abraham B, Marih L, Thevenet S, Marechal Eda S, Verdet C, Rozenbaum W, Pialoux G.

Sex Transm Dis. 2005 Nov;32(11):718-9. No abstract available.

PMID:
16254548
25.

A new insertion in the HIV-1 reverse transcriptase gene inducing major resistance to non-nucleoside reverse transcriptase inhibitors.

Amiel C, Desire N, Schneider V, Delphin N, Race E, Clavel F, Piolot T, Dam E, Rozenbaum W, Nicolas JC.

AIDS. 2005 Nov 4;19(16):1922-4.

PMID:
16227805
26.

Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.

Reliquet V, Ferré V, Hascoet C, Besnier JM, Bellein V, Arvieux C, Molina JM, Breux JP, Zucman D, Rozenbaum W, Allavena C, Raffi F; VIRGO Study Team.

Antivir Ther. 1999;4 Suppl 3:83-4.

PMID:
16021876
27.

Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative.

Laurent C, Meilo H, Guiard-Schmid JB, Mapouré Y, Noël JM, M'Bangué M, Joko A, Rozenbaum W, Ntoné FN, Delaporte E.

Clin Infect Dis. 2005 Jul 1;41(1):108-11. Epub 2005 May 17.

PMID:
15937770
28.

The clinical characteristics of HIV-infected patients receiving dialysis in France between 1997 and 2002.

Vigneau C, Guiard-Schmid JB, Tourret J, Flahault A, Rozenbaum W, Pialoux G, Rondeau E.

Kidney Int. 2005 Apr;67(4):1509-14.

29.

Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.

Molina JM, Journot V, Morand-Joubert L, Yéni P, Rozenbaum W, Rancinan C, Fournier S, Morlat P, Palmer P, Dupont B, Goujard C, Dellamonica P, Collin F, Poizot-Martin I, Chene G; ALIZE (Agence Nationale de Recherches sur le SIDA 099) Study Team.

J Infect Dis. 2005 Mar 15;191(6):830-9. Epub 2005 Feb 10.

PMID:
15717256
30.

Splenic infarction during acute malaria.

Bonnard P, Guiard-Schmid JB, Develoux M, Rozenbaum W, Pialoux G.

Trans R Soc Trop Med Hyg. 2005 Jan;99(1):82-6. Review.

PMID:
15550267
31.

Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients.

Jan V, Cervera P, Maachi M, Baudrimont M, Kim M, Vidal H, Girard PM, Levan P, Rozenbaum W, Lombès A, Capeau J, Bastard JP.

Antivir Ther. 2004 Aug;9(4):555-64.

PMID:
15456087
32.

[There will not be an AIDS vaccine].

Rozenbaum W.

Soins. 2004 Jul-Aug;(687):52. French. No abstract available.

PMID:
15384782
33.

Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). 1983.

Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vézinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L.

Rev Invest Clin. 2004 Mar-Apr;56(2):126-9. No abstract available.

PMID:
15378805
34.

Use of well-defined HIV-derived epitopes to evaluate CD4(+) and CD8(+) T cell responses in patients with chronic HIV-1 infection treated with HAART.

Daniel N, Charmeteau B, Grabar S, Pialoux G, Salmon D, Bonilla N, Dupuis M, Troadec C, Rozenbaum W, Gahéry-Ségard H, Guillet JG, Andrieu M.

AIDS Res Hum Retroviruses. 2004 Aug;20(8):827-35.

PMID:
15320987
35.

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, Jemsek J, Rivero A, Rozenbaum W, Schrader S, Sension M, Vibhagool A, Thiry A, Giordano M.

J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1011-9.

PMID:
15247553
36.

Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.

Wood R, Phanuphak P, Cahn P, Pokrovskiy V, Rozenbaum W, Pantaleo G, Sension M, Murphy R, Mancini M, Kelleher T, Giordano M.

J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):684-92.

PMID:
15167287
37.

BMD is reduced in HIV-infected men irrespective of treatment.

Amiel C, Ostertag A, Slama L, Baudoin C, N'Guyen T, Lajeunie E, Neit-Ngeilh L, Rozenbaum W, De Vernejoul MC.

J Bone Miner Res. 2004 Mar;19(3):402-9. Epub 2003 Dec 22.

38.

Early impairment of CD8+ T cells immune response against Epstein-Barr virus (EBV) antigens associated with high level of circulating mononuclear EBV DNA load in HIV infection.

Legoff J, Amiel C, Calisonni O, Fromentin D, Rajoely B, Abuaf N, Tartour E, Rozenbaum W, Bélec L, Nicolas JC.

J Clin Immunol. 2004 Mar;24(2):125-34.

PMID:
15024179
39.
40.

Peptide insertions in reverse transcriptase pol gene of human immunodeficiency virus type 1 as a rare cause of persistent antiretroviral therapeutic failure.

Schneider V, Legoff J, Bélec L, Delphin N, Dutreuil C, Kara-Mostefa A, Rozenbaum W, Nicolas JC.

Clin Microbiol Infect. 2004 Feb;10(2):127-36.

41.

Emergence of HIV-1 mutated strains after interruption of highly active antiretroviral therapy in chronically infected patients.

Daniel N, Schneider V, Pialoux G, Krivine A, Grabar S, Nguyen TH, Girard PM, Rozenbaum W, Salmon D.

AIDS. 2003 Sep 26;17(14):2126-9. No abstract available.

PMID:
14502019
42.

HIV-1-related spontaneous episodic hypothermia.

Moulignier A, Guiard-Schmid JB, Gbadoe AH, Rozenbaum W.

Neurology. 2003 Aug 12;61(3):418-9. No abstract available.

PMID:
12913216
43.

Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy.

Vigouroux C, Maachi M, Nguyên TH, Coussieu C, Gharakhanian S, Funahashi T, Matsuzawa Y, Shimomura I, Rozenbaum W, Capeau J, Bastard JP.

AIDS. 2003 Jul 4;17(10):1503-11.

PMID:
12824788
44.

[Febrile pseudotumor lesion of the arm. Atypical presentation of Shulman syndrome]].

Seror J, Bonnard P, Baudrimont M, Guiard-Schmid JB, Teixeira A, Rozenbaum W, Pialoux G.

Presse Med. 2003 Mar 22;32(11):498-500. French.

PMID:
12733388
45.

[Liver toxicity of antiretroviral treatments].

Pialoux G, Bonnard P, Rozenbaum W.

Gastroenterol Clin Biol. 2003 Feb;27(2):155-8. Review. French. No abstract available.

46.

High variability of plasma drug concentrations in dual protease inhibitor regimens.

Guiard-Schmid JB, Poirier JM, Meynard JL, Bonnard P, Gbadoe AH, Amiel C, Calligaris F, Abraham B, Pialoux G, Girard PM, Jaillon P, Rozenbaum W.

Antimicrob Agents Chemother. 2003 Mar;47(3):986-90.

47.

HIV-1 related ischaemic trochlear nerve palsy.

Moulignier A, Laloum L, Chauveau E, Gout O, Rozenbaum W.

J Neurol. 2003 Jan;250(1):108-9. No abstract available.

PMID:
12528005
48.

Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue.

Levan P, Nguyen TH, Lallemand F, Mazetier L, Mimoun M, Rozenbaum W, Girard PM.

AIDS. 2002 Sep 27;16(14):1985-7. No abstract available.

PMID:
12351969
49.

[A cost-effectiveness analysis of changes in therapeutic strategies in the treatment of HIV since 1996].

Le Pen C, Rozenbaum W, Downs A, Lilliu H, Maurel F, Foucher F.

Therapie. 2002 Jan-Feb;57(1):27-33. French.

PMID:
12090143
50.

Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors.

Lallemand F, Salhi Y, Linard F, Giami A, Rozenbaum W.

J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):187-90.

PMID:
12045681

Supplemental Content

Loading ...
Support Center